Delivery of interferon alpha using a novel Cox2-controlled adenovirus for pancreatic cancer therapy

Surgery (United States)

Volumn 152, Issue 1, 2012, Pages 114-122

  Armstrong, Leonard ^a   Davydova, Julia ^a,b   Brown, Eric ^a   Han, Joohee ^a   Yamamoto, Masato ^a,b   Vickers, Selwyn M ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; CRYSTAL VIOLET; CYCLOOXYGENASE 2; LUCIFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER THERAPY; COLORIMETRY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR XENOGRAFT; VIRUS MORPHOLOGY; VIRUS REPLICATION; WILD TYPE;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; HUMANS; INTERFERON-ALPHA; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862887525     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.02.017     Document Type: Article

References (25)

1. American Cancer Society. Cancer facts & figures 2010 [homepage on the Internet]. Atlanta: American Cancer Society; 2010. Available from:http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-facts-figures- 2010-rev. Accessed February 22, 2012.
2. Merchant NB, Parikh AA, Liu EH. Adjuvant chemoradiation therapy for pancreas cancer: who really benefits? Adv Surg 2010;44:149-64.
3. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-77.
4. National Comprehensive Cancer NetworkNCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma [homepage on the Internet].: National Comprehensive Cancer Network. Available from: http://www.nccn.org/professionals/ physician-gls/PDF/pancreatic.pdf. Accessed February 22, 2012.
5. Katz MH, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009;16:836-47.
6. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003;8:237-49.
7. Nukui Y, Picozzi VJ, Traverso LW. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2000;179:367-71.
8. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003;185: 476-80.
9. Linehan DC, Tan MC, Strasberg SM, et al. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg 2008;248:145-51.
10. Picozzi VJ, Abrams RA, Decker PA, et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG trial Z05031. Ann Oncol 2010; 22:348-54.
11. Yamamoto M, Davydova J, Wang M, et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003;125:1203-18.
12. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21:139-46.
13. Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001;3:385-94.
14. Wesseling JG, Yamamoto M, Adachi Y, et al. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther 2001;8:990-6.
15. Davydova J, Le LP, Gavrikova T, Wang M, Krasnykh V, Yamamoto M. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res 2004;64:4319-27.
16. Ramirez PJ, Vickers SM, Ono HA, et al. Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Am J Surg 2008;195:481-90.
17. Hatanaka K, Suzuki K, Miura Y, et al. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. J Gene Med 2004;6:1139-48.
18. Ohashi M, Yoshida K, Kushida M, et al. Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer. Br J Cancer 2005;93:441-9.
19. Hara H, Kobayashi A, Yoshida K, et al. Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. Cancer Sci 2007;98:455-63.
20. Narumi K, Kondoh A, Udagawa T, et al. Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer. Cancer Sci 2010;101:1686-94.
21. Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996;7:215-22.
22. Ono HA, Le LP, Davydova JG, Gavrikova T, Yamamoto M. Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region. Cancer Res 2005; 65:10154-8.
23. Davydova J, Gavrikova T, Brown EJ, et al. In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy. Cancer Sci 2010;101:474-81.
24. Maizel JV Jr, White DO, Scharff MD. The polypeptides of adenovirus. I. evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968;36:115-25.
25. Caraglia M, Marra M, Tagliaferri P, et al. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets 2009;9:690-704.